|
www.aurobindo.com |
|
|
|
|
USFDA APPROVAL RECEIVED FOR UNIT
VIII FACILITY |
|
|
|
Aurobindo Pharma Limited has crossed one more
milestone. |
|
We are pleased to announce that US FDA, part of
Department of Health and Human Science, USA has
approved Unit VIII facility of Aurobindo Pharma
Limited as a site to manufacture APIs for the US Market. |
|
Unit VIII consists of 4 production blocks, of
which 3 are geared for APIs for Regulated
markets in the Anti-Retro Virals / CNS / Anti - Allergics / CVS segments. |
|
This is the third approval for Aurobindo Pharma
Limited given by US FDA. The earlier approvals
being for Unit I for APIs and Unit III for
formulations.
|
|
Unit VIII facility is situated at Gaddapotharam
Village, Kazipally – IDA, Jinnaram (Mandal),
Medak District, Andhra Pradesh, India. |
|
|
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited headquartered at
Hyderabad, India manufactures generic
pharmaceuticals and Active Pharmaceutical
Ingredients. The company’s robust product
portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retro Virals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics) with
around 65 APIs in the non-antibiotics and over
55 APIs in the antibiotic segment. The Company
is marketing these products globally, in over
100 countries. |
|
|
|
|
|
PRESS
ROOM
